CD8A and neoplasm: In vitro and in vivo studies using xenografted melanoma tumor models showed that the nanoconjugate can enhance and activate the T-cells in bone marrow-derived dendritic cells to obtain improved CD4 and CD8 antigen expressions via intravenous injection than intratumoral.